Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 149

Results For "LA"

7475 News Found

Lyka Labs swings back to profit in Q1FY23
News | August 09, 2022

Lyka Labs swings back to profit in Q1FY23

The company has reported total income of Rs. 28.20 crores during the period ended June 30, 2022.


Biocon Sdn. Bhd. enters Malaysia Book of Records
Biotech | August 08, 2022

Biocon Sdn. Bhd. enters Malaysia Book of Records

The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR


Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery
Digitisation | August 04, 2022

Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery

The WAVEsystem with the WAVEcontrol 4.0 embedded


Sandu Pharmaceuticals launches Sandu Kumarvin
News | August 04, 2022

Sandu Pharmaceuticals launches Sandu Kumarvin

Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.


Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr
News | August 03, 2022

Fortis Malar Hospitals posts Q1 FY2023 consolidated loss at Rs. 2.96 Cr

The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.


Jubilant Pharmova posts Q1FY23 consolidated PAT at Rs. 47.04 Cr
News | August 03, 2022

Jubilant Pharmova posts Q1FY23 consolidated PAT at Rs. 47.04 Cr

The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.


Jubilant Pharmova gets 6 observations from USFDA for its facility at Roorkee
News | August 03, 2022

Jubilant Pharmova gets 6 observations from USFDA for its facility at Roorkee

he US FDA has issued six observations pursuant to the completion of the audit.


Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes
News | August 02, 2022

Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes

The two generic drugs have been launched under the brand names Jankey & Sitenali.


Shilpa Medicare's Unit III, Advanced Analytical Characterization Laboratory clears US FDA remote record review
Drug Approval | July 31, 2022

Shilpa Medicare's Unit III, Advanced Analytical Characterization Laboratory clears US FDA remote record review

The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing